1. Introduction
Cardiovascular diseases stand as a leading cause of mortality on a global scale. The Global Burden of Disease Study 2017 reported that approximately 17.8 million individuals lost their lives due to cardiovascular conditions, accounting for 31% of all global deaths [
1]. Among these, hypertension, often referred to as the “silent killer”, is a prevalent concern. It is typically characterized by sustained elevations in systolic blood pressure (>140 mmHg) and diastolic blood pressure (>90 mmHg). Major risk factors contributing to hypertension include dyslipidemia, smoking, excessive alcohol consumption, stress, insulin resistance, and the presence of metabolic syndrome [
2].
Renin, a fundamental component of the Renin Angiotensin Aldosterone System (RAAS), originates from the prohormone pro-renin. Its primary role involves catalyzing the conversion of the precursor protein angiotensinogen into angiotensin I. Initially, angiotensin I is an inactive decapeptide, but it undergoes hydrolysis in the presence of angiotensin-converting enzyme (ACE) to transform into the active octapeptide angiotensin II. The ACE inhibition peptide is usually used for hypertension control to prevent the conversion of angiotensin I to angiotensin II [
3]. Angiotensin II serves as a potent vasoconstrictor, primarily interacting with the AT-1 receptor. Additionally, Angiotensin II stimulates the adrenal cortex, prompting the release of aldosterone. This hormone targets the principal cells of the collecting ducts in the nephron, enhancing the reabsorption of both salt and water. This process results in an increase in blood volume, leading to elevated blood pressure [
4].
Metabolic syndrome is a cluster of interconnected risk factors, including obesity, high blood pressure, elevated blood sugar levels, and abnormal lipid profiles. These factors contribute to an increased risk of cardiovascular disease, type 2 diabetes, and other health problems. Oxidative stress is believed to play a role in the development and progression of metabolic syndrome [
5]. The excessive production of free radicals can lead to inflammation, insulin resistance, and damage to blood vessels, all of which are key components of metabolic syndrome. Peroxynitrite (ONOO−), nitrogen oxide (NO*), and hypochlorous acid (HOCl) are produced in everyday metabolic pathways and scavenged through antioxidants [
6]. Superoxide dismutase (SOD) and glutathione peroxidase levels are decreased in newly identified and untreated hypertensive patients, leading to higher oxidative stress. Hydrogen peroxide production is also greater in hypertensive people [
7,
8]. Understanding the link between oxidative stress and metabolic syndrome is essential for developing effective preventive and therapeutic strategies to manage this complex health condition.
Curcumin, a polyphenol found in the rhizome of the herb
Curcuma longa (turmeric), has various pharmacological activities, including cardioprotective, anti-inflammatory, antioxidant, antiseptic, and antimalarial activities. It also helps with pain management [
9,
10]. Curcumin may activate various enzymes involved in the detoxification of electrophilic merchandise of lipid peroxidation (LPO), including glutathione-S-transferase (GST) and glutathione peroxidase (GPx) in rats. This property can also be attributed to its antioxidant activities, which is useful for its antihypertensive recreation [
11]. Simultaneously, it can also inhibit angiotensin-converting enzyme (ACE) [
12]. Thus, drugs with antioxidant properties and ACE inhibitory effects are favored as antihypertensive medicines [
13].
Curcumin effectively exhibits its antioxidant capabilities by scavenging free radicals such as O
2*
− and hydroxyl radicals (OH
*), and by influencing the activity of antioxidant enzymes like GSH, catalase, and SOD, which work to neutralize these radicals [
14]. These effects also contribute to its potential in preventing hypertension. One of the key ways through which curcumin exerts its antihypertensive effects is by inhibiting ACE [
15].
However, curcumin’s clinical utility is significantly hindered due to its limited bioavailability. Studies have shown that a substantial portion (40–85%) of orally administered curcumin remains unchanged as it passes through the gastrointestinal tract. This poor bioavailability can be attributed to factors like low water solubility, inadequate absorption, and rapid elimination [
16]. Researchers have employed various methods to enhance the bioavailability of curcumin. Two common approaches have been pursued to address this challenge. The first approach involves improving curcumin’s transport mechanism (e.g., creating nanoemulsions, curcumin–phospholipid complexes, liposomal curcumin, and chelating with metals). The second approach focuses on altering the structure of curcumin [
17].
Based on the current state-of-the-art curcumin formulations and their impact on the pharmacokinetic profile, curcumin formulations have evolved rapidly to improve their pharmacokinetic (PK) profiles. Researchers have explored various innovative approaches to enhance curcumin’s bioavailability and effectiveness. Some state-of-the-art curcumin formulations and delivery systems that have been developed include nanoparticles. Nanoparticle-based curcumin formulations have gained significant attention. Nanoparticles can protect curcumin from degradation, improve its solubility, and enhance its absorption in the body. Lipid-based nanoparticles, polymeric nanoparticles, and solid lipid nanoparticles are examples of such delivery systems [
18,
19]. Liposomal formulations encapsulate curcumin within lipid bilayers. Liposomes can improve curcumin’s stability and bioavailability by facilitating its transportation across cell membranes [
20]. Micelles: Curcumin can also be incorporated into micelles, which are formed by amphiphilic molecules. Micellar formulations enhance curcumin’s solubility and absorption in the gastrointestinal tract [
21]. Nanoemulsions: Nanoemulsions are colloidal dispersions (10–100 nm in diameter) of oil and water stabilized by surfactants. They can enhance curcumin’s solubility and stability, leading to improved absorption and bioavailability [
22,
23]. Phytosomes: Curcumin phytosomes are complexes formed by combining curcumin with phospholipids. This enhances curcumin’s absorption and bioavailability [
24]. Curcumin-loaded Microspheres: Microspheres are spherical drug carriers that can release curcumin slowly, leading to prolonged therapeutic effects [
25]. Cell-derived vesicles (exosomes): While this technology is relatively new, researchers have been exploring the use of exosomes or cell-derived vesicles in delivering curcumin. These natural vesicles have the potential to improve curcumin’s stability, bioavailability, and targeted delivery [
26]. Polymeric Nanocarriers: Various polymeric nanocarriers, including poly(lactic-co-glycolic acid) (PLGA) nanoparticles, have been employed to encapsulate and deliver curcumin and show improved bioavailability [
27].
The utilization of a self-nanoemulsifying drug delivery system (SNEDDS) holds the potential to enhance bioavailability and improve the effectiveness of lipophilic drugs like curcumin in treating hypertension [
28]. SNEDDS is composed of a mixture of oil, surfactant, and co-surfactant, which, when gently mixed with water, forms a fine oil-in-water (O/W) nanoemulsion [
29]. When taken orally, SNEDDS utilizes the natural motion of the stomach to trigger self-emulsification through agitation [
30]. Several researchers have created formulations of self-nanoemulsifying curcumin (SNEC) and shown that its bioavailability is approximately twice as high as that of curcumin in an aqueous form [
31,
32]. The primary objective of this study was to assess the potential antihypertensive effects of SNEC, which was acquired from Arbro Pharmaceuticals Pvt. Ltd. in the form of SNEC-30 capsules. These effects were then compared with those of established standard drugs: captopril and pure curcumin in an aqueous solution. The hypothesis was that the nanoemulsion formulation of curcumin demonstrates promising attributes as a prospective alternative therapeutic intervention for hypertension.
4. Discussion
To gain deeper insights into the interaction between curcumin and the active site residue of angiotensin-converting enzyme, a molecular docking study was conducted. The docking analyses for all the synthesized compounds were executed using the X-ray crystal structure of human angiotensin-converting enzyme complexed with the selective inhibitor, lisinopril (PDB ID: 1O86, Resolution: 2.00 Å). The GLIDE docking algorithm was employed for these studies. Notably, nearly all the designed compounds exhibited significant and remarkable interactions with the protein backbone.
Curcumin is a phenolic compound that can treat or prevent various diseases such as Alzheimer’s, multiple sclerosis, cataract formation, rheumatoid arthritis, fibrosis, and pulmonary toxicity [
46,
47]. Curcumin has a number of beneficial effects on the cardiovascular system, including blood pressure lowering effect in L-NAME-induced hypertensive rats [
48]. However, curcumin has poor biopharmaceutical properties such as low solubility, poor permeability, and extensive first-pass metabolism [
49]. These obstacles are major hurdles in its clinical application because they reduce its bioavailability. However, this limitation has been overcome by formulating SNED of curcumin. SNED is a novel technique for improving the bioavailability of hydrophobic drugs such as curcumin. It has been reported that the bioavailability of SNEC is much better than that of curcumin [
50].
In this study, we induced hypertension using uninephrectomy and a DOCA salt hypertensive model. This model is widely used for evaluating the cardioprotective effect of various drugs [
51,
52].
The hemodynamic parameters were assessed using an AD instrument. Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate were observed by cannulating the femoral artery. We observed that these hemodynamic readings were increased in the pathogenic group while curcumin shifted these readings toward normal. Our study corroborated previous findings by Berthon et al. [
53]. We also observed that nanoemulsion of curcumin (60 and 90 mg/kg) significantly decreased systolic B.P, diastolic B.P, mean arterial pressure, and heart rate compared with pathogenic rats. This indicates that curcumin nanoemulsions (SNEC) have antihypertensive action against DOCA-induced hypertension. It was also observed that the antihypertensive effect of nanocurcumin was better than that of commercially obtained curcumin.
Left ventricular function was observed by cannulating the carotid artery. DOCA administration significantly increased the LVEDP and decreased LV (dP/dt) max. A rise in LVEDP showed an increased preload or incomplete emptying of the left ventricles, thus left ventricle performance was impaired [
54]. When ventricular performance is impaired, cardiac output is depressed, indicating that there is a deterioration in cardiac performance, which can be a sign of heart failure [
55]. Administration of nanocurcumin (60 and 90 mg) significantly increased the LV (dP/dt) max and reduced the LVEDP, which showed that blood flow was restored to the subendocardial region of the heart and reduced towards normal via reduction of elevated LVEDP.
The kidney plays a pivotal role in regulating the balance between body salt and water. An altered salt–water balance causes disordered regulation of renal functions, which may lead to hypertension [
56]. Hypertensive rats elevate plasma/serum levels of urea, uric acid, and creatinine, which are considered significant markers of renal function. Renal marker levels were significantly disturbed in the sera of DOCA-induced hypertensive rats; after treatment with nanocurcumin, these marker levels shifted significantly toward normal levels.
Oxidative stress plays a crucial role in both the commencement and progression of cardiovascular dysfunction. Elevated levels of reactive oxygen species (ROS) such as superoxide anion, hydrogen peroxide, and lipid peroxides become prevalent during instances of oxidative stress, thereby fostering the development of hypertension. In this context, the balance between ROS production and the efficacy of antioxidant defense mechanisms becomes perturbed, thereby magnifying the influence of oxidative stress [
57]. The generated ROS induces oxidative deterioration in polyunsaturated fatty acids (PUFAs), which are linked with altered membrane structure and enzyme inactivation. Thus, lipid peroxidation is an important pathogenic event during hypertension. Thiobarbituric acid reactive substances (TBARS) and lipid hydroperoxides are the end products of lipid peroxidation; their concentrations were highly elevated in the plasma and tissues of DOCA-induced rats, indicating high oxidative stress in DOCA-induced rats. Nanocurcumin (60 and 90 mg/kg) treatment decreases the levels of lipid peroxidation products in DOCA-induced rats. This evidence suggests that the antihypertensive action of nanocurcumin would be at least partially due to its antioxidant potential.
The activities of SOD, CAT, and GSH were significantly decreased in rats induced with DOCA compared with rats in the control group. This decline indicates a reduced capacity to counteract active oxygen species and reactive metabolites, implying a weakened defense mechanism against oxidative stress in DOCA-induced hypertensive rats.
Histopathological analysis of hearts treated with DOCA revealed extensive modifications in the myocardial structure. These changes encompassed cardiac myocyte hypertrophy, separation of cardiac muscle fibers, interstitial edema, fibrosis, necrosis, and infiltration of inflammatory cells, consistent with findings from prior research. On the other hand, hearts treated solely with curcumin per se and nanocurcumin per se displayed normal cardiac fibers without any pathological indications, suggesting that neither curcumin nor nanocurcumin had a notable impact on the myocardium itself. However, when nanocurcumin was administered orally as a therapeutic intervention, it notably ameliorated the cardiac injury induced by DOCA, thus confirming its beneficial effects in protecting the heart.
Histopathological examination of kidneys in rats induced with DOCA salt reveals several notable findings, including tubular cell atrophy, dilation of distal convoluted tubule lumens, and glomerular congestion. In contrast, animals treated with nanocurcumin exhibit normal glomerular and tubular epithelial morphology. This observation confirms the nephroprotective effect of nanocurcumin and its potential in hypertension treatment.